Altimmune, Inc. · NASDAQ:ALT
Altimmune — Investor Presentation (June 2020)
10 slides from Altimmune's investor presentation, June 2020
Slide 1: T-COVID: Single-Dose Intranasal Therapeutic for Early COVID-19
T-COVIDTM SINGLE-DOSE INTRANASAL THERAPEUTIC FOR THE TREATMENT OF EARLY COVID-19 NASDAQ: ALT June 2020
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Safe-Harbor Statement Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializin
Slide 3: T-COVID: Based on RD-Ad5 Vector Vaccine Platform
T-COVIDTM: BASED ON RD-Ad5 VECTOR VACCINE PLATFORM SINGLE DOSE INTRANASAL THERAPEUTIC FOR THE TREATMENT OF EARLY COVID-19 • Identical vector technology used for AdCOVID (COVID-19), NasoVAX (seasonal influenza) and NasoShield (anthrax) vaccines AdCOVID Ad5 CMV SV40- Ad5 Ad5 Promoter poly A NasoVAX Na
Slide 4: T-COVID: Modulates Innate Immunity in Animal Models
T-COVIDTM: MODULATES INNATE IMMUNITY IN ANIMAL MODELS PRECLINICAL STUDIES FUNDED BY NIAID & CONDUCTED AT UTAH STATE UNIVERSITY Data from 6 preclinical studies of influenza infection funded by NIAID and conducted at Utah State University showed: • Rapid, non-antigen mediated modification of host cyto
Slide 5: Protection Established in Animals Within 2 Days
PROTECTION ESTABLISHED IN ANIMALS WITHIN 2 DAYS EFFECTS SEEN WITH ADMINISTRATION OF EITHER EMPTY VECTOR OR NasoVAX Experimental design Empty vector Day -2 Day -2 or Day -22 • Intranasal administration (2.5 x108 ifu) of either empty vector (vector without antigen) or NasoVAX (vector with antigen) Emp
Slide 6: Reduced Influenza-Induced Lung Inflammation
REDUCED INFLUENZA-INDUCED LUNG INFLAMMATION EFFECT SEEN WITH ADMINISTRATION OF EITHER EMPTY VECTOR OR NasoVAX RD-Ad5 Vector Treatment: None None Empty Vector NasoVAX Influenza Challenge: Yes No Yes Yes • Intranasal administration of either empty vector or Low mag NasoVAX on Day -2 • Challenge with i
Slide 7: Decreased Inflammatory Cytokines in Lungs
DECREASED INFLAMMATORY CYTOKINES IN LUNGS RD-Ad5 VECTORS MODULATE THE INNATE IMMUNE RESPONSE TO INFECTION Placebo (2 days pre-challenge) Empty vector (2 days pre-challenge) IL-6 IL-12p70 IL-1α * ** ** ** Balb/c mice administered an intranasal dose of RD-Ad5 (3.2 x 108 ifu) on Day -2 and challenged w
Slide 8: Target Product Profile
TARGET PRODUCT PROFILE Indications: Prevention of clinical worsening and hospitalization of ambulatory patients with early COVID-19 Prevention of COVID-19 in individuals at high-risk of infection (known exposures) Potential first-line community protection against future strains of coronavirus and ot
Slide 9: Phase 1/2 Clinical Trial Design
PHASE 1/2 CLINICAL TRIAL DESIGN • 96 community-based patients with fever, cough, or shortness of breath, with onset of symptoms within 48 hours, and a diagnosis of COVID-19 within 24 hours, will be randomized 1:1 to NasoVAX or placebo administered as a single 0.5 mL nasal spray on the day of diagnos
Slide 10: T-COVID: Single-Dose Intranasal Therapeutic for Early COVID-19
T-COVIDTM SINGLE-DOSE INTRANASAL THERAPEUTIC FOR THE TREATMENT OF EARLY COVID-19 NASDAQ: ALT June 2020